A reported MDMA concentration can establish that the drug was present in a blood specimen. A different question is whether the number, by itself, establishes that the driver was impaired. A 2024 Journal of Analytical Toxicology study provides a useful real-world answer: in this dataset, the investigators could not demonstrate a significant relationship between MDMA concentration and a physician’s clinical impairment assessment.
The investigators reviewed Norwegian driving-under-the-influence cases from 2000 through 2022. Whole-blood specimens were analyzed for cocaine and MDMA, and a physician performed a clinical test of impairment at approximately the same time. MDMA was detected in 2,569 cases. Because other substances can confound interpretation, the concentration–impairment analysis focused on 85 cases in which MDMA was the only detected drug.
In those 85 MDMA monodrug cases, the median concentration was 0.19 mg/L, with a range from 0.04 to 1.36 mg/L. Physicians classified 32 drivers as impaired, 50 as not impaired, and three as impossible to classify. Thus, 38% of the monodrug cases were assessed as impaired.
No statistically significant relationship was found. The median MDMA concentration was actually higher in the group assessed as not impaired—0.24 mg/L—than in the group assessed as impaired—0.19 mg/L. That difference was not statistically significant (P = 0.816). The correlation between concentration and degree of impairment was also not significant, and the multivariable model did not identify MDMA concentration, age, sex, or time of driving as significant predictors of the clinical assessment.
This does not mean MDMA cannot impair driving. It means the measured concentration did not reliably sort these drivers into clinically impaired and unimpaired groups.
A blood result is a specimen measurement taken at a particular time. Driving behavior occurred earlier. Dose, time of ingestion, repeated dosing, absorption, metabolism, tolerance, sleep loss, environment, and the interval between driving and blood collection can all affect the relationship between the measured number and the driver’s functional state. MDMA may also produce mixed effects: stimulation can temporarily improve some simple measures while risk taking, speed choice, divided attention, tracking, or judgment worsens.
The broader dataset also showed how often co-use complicates interpretation. Among all MDMA-positive cases, amphetamine was detected in 63%, THC in 48%, clonazepam in 33%, and ethanol in 15%. A toxicologist should therefore evaluate the complete analytical profile rather than treating MDMA in isolation when multiple substances are present.
The study was naturalistic, not a controlled dosing experiment. The researchers lacked information about dose, ingestion time, prior experience, use pattern, and some health conditions. Different physicians performed the clinical examinations, and only the overall conclusion—not the individual subtest results—was available. The authors also noted that several clinical-test components are better suited to detecting sedating drugs than stimulants. Finally, the MDMA monodrug subgroup was only 85 cases, much smaller than the complete MDMA-positive population.
The defensible interpretation separates four questions:
The study supports a careful conclusion: a whole-blood MDMA concentration is relevant evidence of exposure, but the number alone did not predict the clinical impairment classification in this real-world sample.
Heide G, et al. “Driving under the influence of cocaine and MDMA: Relationship between blood concentrations and results from clinical test of impairment.” Journal of Analytical Toxicology (2024). PMID 38613441. PubMed record | Full text | DOI: 10.1093/jat/bkae024.